Chief Development Officer · Trevi Therapeutics, Inc. (TRVI)

Pharm. William Forbes

FY2021 is the first fiscal year CompBrief holds for Pharm. William Forbes as a named executive officer of Trevi Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,180,794

Salary $406,731Bonus $153,000

2nd of 3 named executive officers at Trevi Therapeutics by FY2021 total.

3 named officers on file for Trevi Therapeutics, FY2021

Pharm. William Forbes’s pay file — $29

  • 1 fiscal year of pay, line by line
  • TRVI’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Trevi Therapeutics’s whole pay program stands against its peers

  • Trevi Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TRVI→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2022 (DEF 14A).

Free

Get Pharm. William Forbes’s full pay file as a PDF — free

More than this page: up to 10 years of Pharm.’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Pharm. William Forbes compensation by year

Trevi Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Trevi Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$406,731
Bonus$153,000
Option awards$621,063
All other$0
Total$1,180,794

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Trevi Therapeutics, Inc. DEF 14A filed April 29, 2022, accession 0001564590-22-016859, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Trevi Therapeutics, Inc. filed document, accession 0001564590-22-016859. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2022.

Trevi Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Jennifer GoodPresident and Chief Executive Officer$1,527,439
Pharm. William Forbes · this pageChief Development Officer$1,180,794
Thomas SciasciaChief Medical Officer$717,544

The full Trevi Therapeutics compensation record

free company brief

This page is one person within Trevi Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Trevi Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Trevi Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Pharm. William Forbes's compensation dossier · One-time report. No refunds.